Johnson & Johnson (JNJ) Stock Price & Analysis
Johnson & Johnson (JNJ) rose 1.59% to USD 263.4 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
JNJ last closed at USD 259.27; the session ranged USD 259.61–263.68 on volume of 6,347,637 shares. Market capitalization is $634.77B, with a 52-week range of USD 164.23–269.43 (NYQ). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 263.4 |
|---|---|
| Change | ▲ 1.59% (up) |
| Previous Close | USD 259.27 |
| Open | USD 261.43 |
| Day Range | USD 259.61 – 263.68 |
| 52-Week Range | USD 164.23 – 269.43 |
| Volume | 6,347,637 shares |
| Market Cap | $634.77B |
| Exchange | NYQ |
Technical Analysis (JNJ)
Nexqual's technical model rates JNJ "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.82 (neutral) |
| vs SMA50 | Above (USD 241.93) |
| MACD | 4.03 (positive) |
Analyst Ratings (JNJ)
Wall Street analysts rate JNJ "Buy" based on 22 analysts, with a mean price target of USD 270.59 (range USD 190–305), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 22 |
| Mean Target | USD 270.59 |
| High Target | USD 305 |
| Low Target | USD 190 |
| Buy / Hold / Sell | 16 / 6 / 1 |
Earnings (JNJ)
| Next Earnings Date | 2026-10-13 |
|---|---|
| EPS Estimate | USD 3.05 |
| Revenue Estimate | $25.32B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.9 vs est 2.85 ▲ beat |
| 2026-03-31 | USD 2.7 vs est 2.68 ▲ beat |
| 2025-12-31 | USD 2.46 vs est 2.46 ▼ miss |
| 2025-09-30 | USD 2.8 vs est 2.76 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (JNJ)
| Total Revenue | $97.93B |
|---|---|
| Revenue Growth (YoY) | +6.60% |
| Gross Margin | +68.10% |
| Operating Margin | +28.61% |
| Profit Margin | +21.48% |
| Debt / Equity | 67.73 |
| Total Cash | $22.05B |
| Total Debt | $54.99B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (JNJ)
Nexqual rates Johnson & Johnson's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 29% |
| Balance Sheet | Solid — $22.1B cash vs $55.0B debt |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (JNJ)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +76.83% |
| Shares Outstanding | 2.41B |
| Float | 2.40B |
| Short % of Float | +1.23% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (JNJ)
Johnson & Johnson is led by Joaquin Duato (age 62), CEO & Chairman, per Nexqual as of July 25, 2026 at 01:13 UTC.
| CEO & Chairman | Joaquin Duato (age 62) |
|---|---|
| Executive VP & CFO | Joseph James Wolk (age 58) |
| Executive VP & Worldwide Chairman of Innovative Medicine | Jennifer L. Taubert (age 61) |
| Executive Vice President of Innovative Medicine and R & D | John C. Reed (age 67) |
| Executive VP & Worldwide Chairman of MedTech | Timothy Schmid (age 55) |
Major Backers & Investors (JNJ)
Notable institutional backers of Johnson & Johnson include JPMorgan, Morgan Stanley, State Farm Mutual Automobile Insurance Co, according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 3.01% |
| Morgan Stanley | 1.86% |
| State Farm Mutual Automobile Insurance Co | 1.31% |
| Fidelity | 1.28% |
| Bank of America Corporation | 1.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.92% |
| BlackRock | 10.18% |
| State Street | 6.75% |
| Geode Capital | 2.46% |
| Northern Trust | 1.22% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Johnson & Johnson's Latest SEC 10-K Filing (filed 2026-02-11)
Partnerships
- In January 2026, the Company reached an agreement with the U.S.
- Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PG | Procter & Gamble Company (The) | USD 147.41 | ▼ 1.15% |
| PFE | Pfizer, Inc. | USD 24.54 | ▼ 1.13% |
| MRK | Merck & Company, Inc. | USD 131.07 | ▲ 2.82% |
| KO | Coca-Cola Company (The) | USD 82.25 | ▲ 0.06% |
| XOM | ExxonMobil Holdings Corporation | USD 156.94 | ▲ 1.61% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.